arGEN-X Plans IPO To Progress Pipeline And Attract Fresh Partnerships
This article was originally published in The Pink Sheet Daily
Dutch antibody therapeutics developer arGEN-X BV will use proceeds from a planned summer IPO to progress three clinical assets and further develop its strategy targeting orphan indications, while adding to its growing list of big pharma partners in major indications.
You may also be interested in...
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.
The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.